Home > Compound List > Product Information
Prostratin_Molecular_structure_CAS_60857-08-1)
Click picture or here to close

Prostratin

Catalog No. P0077 Name Sigma Aldrich
CAS Number 60857-08-1 Website http://www.sigmaaldrich.com
M. F. C22H30O6 Telephone 1-800-521-8956
M. W. 390.47 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 129142

SYNONYMS

IUPAC name
(1R,2S,6R,10S,11R,13S,15R)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dien-13-yl acetate
IUPAC Traditional name
prostratin
Synonyms
NSC 623310
CCRIS 6292
12-Deoxyphorbol-13-acetate

DATABASE IDS

MDL Number MFCD00674138
CAS Number 60857-08-1

PROPERTIES

Empirical Formula (Hill Notation) C22H30O6
Purity ≥98% (HPLC)
Apperance white powder
Solubility DMSO: soluble30 mg/mL
MSDS Link Download
Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
Storage Temperature -20°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Prostratin, an unusual non-tumorigenic phorbol ester, is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). Prostratin exhibits potent in vitro activity by inducing HIV expression in latently infected cell lines and primary cells, thus antagonizing HIV latency. Activation of PKC and NF-kB has been proposed as the mechanism of action. Prostratin also inhibits HIV entry into target cells by down-regulating CD4 and CXCR4 receptors.
Description (简体中文)
Biochem/physiol Actions
Prostratin, an unusual non-tumorigenic phorbol ester, is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). Prostratin exhibits potent in vitro activity by inducing HIV expression in latently infected cell lines and primary cells, thus antagonizing HIV latency. Activation of PKC and NF-kB has been proposed as the mechanism of action. Prostratin also inhibits HIV entry into target cells by down-regulating CD4 and CXCR4 receptors.

REFERENCES